CHRS
Price
$0.70
Change
-$0.07 (-9.09%)
Updated
Nov 15, 03:14 PM (EDT)
104 days until earnings call
SONN
Price
$3.00
Change
-$0.08 (-2.60%)
Updated
Nov 14 closing price
Ad is loading...

CHRS vs SONN

Header iconCHRS vs SONN Comparison
Open Charts CHRS vs SONNBanner chart's image
Coherus BioSciences
Price$0.70
Change-$0.07 (-9.09%)
Volume$2.49K
CapitalizationN/A
Sonnet BioTherapeutics Holdings
Price$3.00
Change-$0.08 (-2.60%)
Volume$94.11K
CapitalizationN/A
CHRS vs SONN Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CHRS vs. SONN commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and SONN is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (CHRS: $0.77 vs. SONN: $3.00)
Brand notoriety: CHRS and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 87% vs. SONN: 16%
Market capitalization -- CHRS: $89.01M vs. SONN: $2.05M
CHRS [@Biotechnology] is valued at $89.01M. SONN’s [@Biotechnology] market capitalization is $2.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileSONN’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • SONN’s FA Score: 1 green, 4 red.
According to our system of comparison, SONN is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while SONN’s TA Score has 2 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 2 bearish.
  • SONN’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than SONN.

Price Growth

CHRS (@Biotechnology) experienced а -5.78% price change this week, while SONN (@Biotechnology) price change was -18.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.07%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +5.23%.

Reported Earning Dates

CHRS is expected to report earnings on Feb 27, 2025.

SONN is expected to report earnings on Nov 29, 2023.

Industries' Descriptions

@Biotechnology (-2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($89M) has a higher market cap than SONN($2.05M). CHRS (-76.799) and SONN (-78.448) have similar YTD gains .
CHRSSONNCHRS / SONN
Capitalization89M2.05M4,346%
EBITDAN/AN/A-
Gain YTD-76.799-78.44898%
P/E RatioN/A0.29-
RevenueN/AN/A-
Total CashN/A3.55M-
Total DebtN/A150K-
FUNDAMENTALS RATINGS
CHRS vs SONN: Fundamental Ratings
CHRS
SONN
OUTLOOK RATING
1..100
5550
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9496
P/E GROWTH RATING
1..100
6896
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SONN's Valuation (24) in the null industry is significantly better than the same rating for CHRS (91) in the Biotechnology industry. This means that SONN’s stock grew significantly faster than CHRS’s over the last 12 months.

SONN's Profit vs Risk Rating (100) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that SONN’s stock grew similarly to CHRS’s over the last 12 months.

SONN's SMR Rating (100) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that SONN’s stock grew similarly to CHRS’s over the last 12 months.

CHRS's Price Growth Rating (94) in the Biotechnology industry is in the same range as SONN (96) in the null industry. This means that CHRS’s stock grew similarly to SONN’s over the last 12 months.

CHRS's P/E Growth Rating (68) in the Biotechnology industry is in the same range as SONN (96) in the null industry. This means that CHRS’s stock grew similarly to SONN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSSONN
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with PRME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-0.78%
PRME - CHRS
44%
Loosely correlated
-9.22%
SWTX - CHRS
40%
Loosely correlated
+5.30%
QSI - CHRS
40%
Loosely correlated
-1.52%
MGTX - CHRS
40%
Loosely correlated
-5.68%
DNLI - CHRS
39%
Loosely correlated
-3.98%
More

SONN and

Correlation & Price change

A.I.dvisor tells us that SONN and SNBIF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SONN and SNBIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-2.60%
SNBIF - SONN
28%
Poorly correlated
N/A
NTLA - SONN
27%
Poorly correlated
-6.15%
PRME - SONN
27%
Poorly correlated
-9.22%
CHRS - SONN
26%
Poorly correlated
-0.78%
ABCL - SONN
26%
Poorly correlated
-5.48%
More